Status:
UNKNOWN
CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The aim of the study is to examine whether tamoxifen-treated Israeli breast cancer patients who are CYP2D6 poor metabolizers (CYP2D6\*4/\*4 genotype) are at higher cancer relapse risk during 2.5-5-yea...
Detailed Description
Tamoxifen, the first-line drug for preventing breast cancer relapse, is typically prescribed for a 5-year follow-up period after diagnosis and primary treatment of estrogen receptor-positive breast ca...
Eligibility Criteria
Inclusion
- Female
- Age \> 18
- Treated with Tamoxifen following diagnosis of breast cancer
Exclusion
- None
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00815555
Start Date
December 1 2008
Last Update
December 30 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Pharmacology Unit - Assaf Harofeh Medical Center
Ẕerifin, Israel, 70300